Another research simultaneous genotypic screening of three gene mutations, including ROS1, ALK and EGFR, to measure the prevalence and clinicopathologic features of ROS1 mutations and immunotherapy efficacy in NSCLC patients (Lee et al., 2019). This evidence concerns the gene EGFR and non-small cell lung carcinoma.